Gilead’s 4-drug combination pill Quad for HIV achieves endpoint
Earlier on Monday, Gilead Sciences Inc. announced that a late-stage study for a 4-drug combination pill “Quad,” intended to treat
Read moreEarlier on Monday, Gilead Sciences Inc. announced that a late-stage study for a 4-drug combination pill “Quad,” intended to treat
Read moreNEW YORK (AP) —Gilead Sciences Inc. announced that the manufacturing issues highlighted in the FDA warning letter in September have
Read moreIn an announcement earlier on Wednesday, Gilead said that Complera, the once-per-day combination treatment for HIV, has been approved by
Read more